A single dose of evolocumab administered early post-myocardial infarction significantly reduced myocardial inflammation at 30 days by 26.7% compared to a 10.4% reduction with placebo.
RCT (n=55)
Double-blind
Stratified randomization
Yes
Does early in-hospital PCSK9 inhibition reduce myocardial inflammation and influence cardiac remodeling in patients after myocardial infarction?
Early in-hospital PCSK9 inhibition may reduce post-MI myocardial inflammation and influence subsequent cardiac remodeling.
Absolute Event Rate: -26.7% vs -10.4%
p-value: p=0.041
was linked to increased end-systolic volume at 6 months. These findings suggest that early PCSK9 inhibition reduces post-MI myocardial inflammation and may influence cardiac remodeling in the months following the acute event.
Ziogos et al. (Sat,) conducted a rct in Acute Myocardial Infarction (STEMI or NSTEMI) (n=55). Evolocumab vs. Placebo was evaluated on Percentage change in myocardial inflammation (SUVmean) from baseline to 30 days (p=0.041). A single dose of evolocumab administered early post-myocardial infarction significantly reduced myocardial inflammation at 30 days by 26.7% compared to a 10.4% reduction with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: